Hemoglobin A1C Variability as a Risk Factor for Diabetes Complications
血红蛋白 A1C 变异是糖尿病并发症的危险因素
基本信息
- 批准号:10631268
- 负责人:
- 金额:$ 25.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAffectAgeAnticoagulationBenefits and RisksBlood PressureCardiovascular DiseasesCaringCharacteristicsClinicalClinical Practice GuidelineClinical TrialsComplexComplications of Diabetes MellitusDevelopmentDiabetes MellitusElderlyEquilibriumEventGlycosylated hemoglobin AGoalsHealthHealthcare SystemsHyperglycemiaHypoglycemiaIntuitionKidney DiseasesLDL Cholesterol LipoproteinsLinkMeasuresMediatingMediator of activation proteinMethodsMicrovascular DysfunctionMonitorMyocardial InfarctionOrganOutcomePatientsPatternPharmaceutical PreparationsProcessProviderQuality ControlQuality of CareRHOA geneResearchRetinal DiseasesRiskRisk FactorsSamplingSelection BiasStatistical MethodsStrokeTechniquesTestingTimeUnited States Department of Veterans AffairsVariantadverse outcomebaseblood glucose regulationcholesterol controldesigndiabetes riskhealth managementindividual patientindividualized medicineinterestmacrovascular diseasemedication compliancemortalitymortality risknovelpoint of carepopulation healthpreventrisk stratificationstandard measuresystematic review
项目摘要
Persistent hyperglycemia predicts the development of microvascular complications (e.g. retinopathy and
nephropathy) in patients with diabetes. However, the relationship between glucose control and organ damage
is complex. Reducing hemoglobin A1c (A1c) prevents or delays microvascular complications but
cardiovascular disease (CVD) and mortality are inconsistently affected. Thus, there is a need to develop new
quality measures beyond A1c alone to better identify and treat patients at risk for complications and mortality.
A1c variability, as measured by fluctuations in A1c over time, is a strong candidate. Several studies show a
significant relationship between increased A1c variability and microvascular disease and CVD. While A1c
variability carries important risk information, variance measures such as standard deviation, may not be
clinically intuitive. Thus, our goal is to develop a new quality measure of A1c variability – A1c time in range
(TIR) – that helps clinicians and patients control A1c in a way that balances long-term benefits and risks. We
will define A1c TIR as the percentage of days a patient's A1c levels are in a specific target range, based on
their clinical characteristics and clinical practice guidelines. We will study A1c TIR in a generalizable
nationwide sample of over 365,000 patients from the Department of Veterans Affairs and Kaiser Permanente.
We will apply advanced statistical methods that stringently control for selection bias by using an instrumental
variable design, including process quality controls. These methods allow us to draw causal inferences between
TIR and risk of new diabetes complications. We will study the predictors of A1c TIR, which we hypothesize will
be affected by provider practice patterns, individual patient-level characteristics and medications. We will test
the hypothesis that higher A1c TIR confers lower risk of diabetes complications. We will also study the
converse – A1c time out-of-range (TOR), with interest in deviations both above (TOR [high]) and below the
range (TOR [low]) to determine if either is uniquely associated with micro- or macrovascular complications.
Then we will investigate clinical factors, hypoglycemic events and rapid declines in A1c, as mediators of the
relationship between TIR and adverse outcomes. Each is linked to mortality and early worsening of diabetes
complications, respectively. This study will advance diabetes care by developing a novel quality measure that
identifies patients in a risk-stratified way and helps clinicians tailor diabetes treatment based on a patient's
unique goals of care. Such a new measure will be used by clinicians at the point-of-care and by healthcare
systems for population health management.
持续性高血糖可预测微血管并发症(如视网膜病变和
糖尿病患者的肾脏疾病。然而,血糖控制与器官损伤之间的关系
相当复杂.降低血红蛋白A1 c(A1 c)可预防或延迟微血管并发症,
心血管疾病(CVD)和死亡率的影响并不一致。因此,需要开发新的
质量措施超越A1 c单独,以更好地识别和治疗有并发症和死亡风险的患者。
A1 c变异性,如A1 c随时间的波动所测量的,是一个强有力的候选者。一些研究表明,
A1 c变异性增加与微血管疾病和CVD之间存在显著相关性。A1c
变异性携带重要的风险信息,方差度量(如标准差)可能不
临床直觉。因此,我们的目标是开发一种新的A1 c变异性质量指标-A1 c范围内时间
(TIR)- 帮助临床医生和患者以平衡长期利益和风险的方式控制A1 c。我们
将A1 c TIR定义为患者A1 c水平处于特定目标范围内的天数百分比,基于
其临床特征和临床实践指南。我们将研究A1 c TIR在一个概括的
来自退伍军人事务部和Kaiser Permanente的365,000多名患者的全国样本。
我们将应用先进的统计方法,通过使用仪器,严格控制选择偏差。
变量设计,包括过程质量控制。这些方法使我们能够得出因果推论之间
TIR和新发糖尿病并发症的风险。我们将研究A1 c TIR的预测因素,我们假设这将
受提供者实践模式、个体患者水平特征和药物的影响。我们将测试
假设较高的A1 c TIR可以降低糖尿病并发症的风险。我们亦会研究
匡威-A1 c时间超出范围(TOR),对高于(TOR [高])和低于
范围(TOR [低]),以确定是否与微血管或大血管并发症唯一相关。
然后,我们将研究临床因素,低血糖事件和A1 c的快速下降,作为介导因素,
TIR与不良结局之间的关系。每一种都与死亡率和糖尿病的早期恶化有关
并发症,分别。这项研究将通过开发一种新的质量测量方法来促进糖尿病护理,
以风险分层的方式识别患者,并帮助临床医生根据患者的
独特的护理目标。这种新的措施将被临床医生在护理点和医疗保健使用
人口健康管理体系。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL R CONLIN其他文献
PAUL R CONLIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL R CONLIN', 18)}}的其他基金
Comparative and cost effectiveness of diabetes medications
糖尿病药物的比较和成本效益
- 批准号:
10620191 - 财政年份:2022
- 资助金额:
$ 25.78万 - 项目类别:
Comparative and cost effectiveness of diabetes medications
糖尿病药物的比较和成本效益
- 批准号:
10417481 - 财政年份:2022
- 资助金额:
$ 25.78万 - 项目类别:
Hemoglobin A1C Variability as a Risk Factor for Diabetes Complications
血红蛋白 A1C 变异是糖尿病并发症的危险因素
- 批准号:
10664333 - 财政年份:2022
- 资助金额:
$ 25.78万 - 项目类别:
Hemoglobin A1C Variability as a Risk Factor for Diabetes Complications
血红蛋白 A1C 变异是糖尿病并发症的危险因素
- 批准号:
10356077 - 财政年份:2019
- 资助金额:
$ 25.78万 - 项目类别:
CARDIOVASCULAR AND RENAL HEMODYNAMICS AND THE DASH DIET
心血管和肾脏血流动力学以及短跑饮食
- 批准号:
7719351 - 财政年份:2008
- 资助金额:
$ 25.78万 - 项目类别:
CARDIOVASCULAR AND RENAL HEMODYNAMICS AND THE DASH DIET
心血管和肾脏血流动力学以及短跑饮食
- 批准号:
7607409 - 财政年份:2007
- 资助金额:
$ 25.78万 - 项目类别:
Cardiovascular and renal hemodynamics and the DASH diet
心血管和肾脏血流动力学以及 DASH 饮食
- 批准号:
6920346 - 财政年份:2005
- 资助金额:
$ 25.78万 - 项目类别:
Cardiovascular and renal hemodynamics and the DASH diet
心血管和肾脏血流动力学以及 DASH 饮食
- 批准号:
7225229 - 财政年份:2005
- 资助金额:
$ 25.78万 - 项目类别:
Cardiovascular and renal hemodynamics and the DASH diet
心血管和肾脏血流动力学以及 DASH 饮食
- 批准号:
7405373 - 财政年份:2005
- 资助金额:
$ 25.78万 - 项目类别:
Cardiovascular and renal hemodynamics and the DASH diet
心血管和肾脏血流动力学以及 DASH 饮食
- 批准号:
7059356 - 财政年份:2005
- 资助金额:
$ 25.78万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 25.78万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 25.78万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 25.78万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 25.78万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 25.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 25.78万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 25.78万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 25.78万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 25.78万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 25.78万 - 项目类别:
Miscellaneous Programs